Hims & Hers are taking grip on Telemedicine

Catalysts

Financial Performance:

• In 2023, Hims & Hers reported impressive financial results:
  • Revenue: Reached $872.0 million, reflecting a 65% year-over-year increase.
  • Net Income: Achieved $1.2 million in Q4 2023.
  • Adjusted EBITDA Profitability: Stood at $20.6 million in Q4 2023.
  • Subscribers: Grew to 1.5 million, up 48% year-over-year in Q4 2023.
• The company provided 2024 guidance, projecting full-year revenue in the range of $1.17 billion to $1.20 billion and Adjusted EBITDA in the range of $100 million to $120 million.

Industry Tailwinds:

• Telemedicine: Hims & Hers leverages telemedicine, which is a significant industry tailwind. Telemedicine allows patients to access licensed physicians conveniently via smartphones or computers, breaking down barriers related to high copays, long wait times, and accessibility.
• Patient Engagement: Their model emphasizes patient engagement, allowing users to actively participate in decisions about their health. Evidence suggests that engaged patients achieve better outcomes and lower costs.
• Brand Strength: The Hims & Hers brand resonates with customers, driving unique flywheel dynamics. Their omni-channel presence and authentic messaging contribute to their success.
• Weight Management Business: The company sees a long-term tailwind from their weight management business, which is expected to play a significant role in the coming years.

In summary, Hims & Hers Health’s robust financials, strategic focus on personalized care, and alignment with industry trends position them well for continued growth. Their mission to make healthcare accessible and affordable through telemedicine remains a powerful driver of success.

Assumptions

Revenue Projection:

• Hims & Hers Health’s revenue growth has been robust, driven by their telemedicine platform and personalized care offerings.
• Assuming continued market penetration, expansion into new services, and sustained customer engagement, we can make an estimate.
• Let’s use a conservative annual growth rate (CAGR) approach:
  • Current Revenue (2023): $872 million
  • Assumed CAGR: Let’s consider a moderate growth rate of 20% per year.
  • Using the formula:Projected Revenue in 5 years=Current Revenue×(1+CAGR)Number of YearsProjected Revenue in 2028=872×(1+0.20)5≈$2.4 billion

Therefore, in 5 years, Hims & Hers Health’s revenue could potentially reach around $2.4 billion.

Earnings Projection:

• Earnings (profit) depend on various factors, including revenue growth, cost management, and operational efficiency.
• Let’s assume that the company maintains its current profit margin (net income as a percentage of revenue).
• Current Net Income (2023): $1.2 million (Q4 2023)
• Assuming the same profit margin:
  • Projected Net Income in 2028:Projected Net Income in 2028=Projected Revenue in 2028×Profit MarginProjected Net Income in 2028=$2.4 billion×872 million1.2 million​≈$3.3 million

Therefore, in 5 years, Hims & Hers Health’s net income could potentially be around $3.3 million.

Risks

Regulatory Risks:

• Telemedicine Regulations: The regulatory environment for telemedicine is evolving. Changes in licensing requirements, reimbursement policies, or restrictions on virtual care could affect Hims & Hers’ operations.
• Privacy and Data Security: As a healthcare company, Hims & Hers must comply with strict privacy laws (e.g., HIPAA in the U.S.). Any data breaches or non-compliance could lead to legal and reputational risks.

Competitor Risks:

• Increased Competition: The telehealth space is competitive. Established players (e.g., Teladoc, Amwell) and new entrants could intensify competition, impacting market share and pricing.
• Vertical Integration: Traditional healthcare providers or pharmacy chains entering telemedicine may pose a threat. For example, CVS Health’s MinuteClinic offers virtual visits.
• Brand Differentiation: Maintaining a unique brand identity is crucial. If competitors replicate Hims & Hers’ model successfully, it could erode their competitive advantage.

Market Risks:

• Market Saturation: As telemedicine gains popularity, saturation in certain markets may occur. Hims & Hers needs to diversify its offerings to sustain growth.
• Healthcare Policy Changes: Changes in healthcare policies (e.g., universal healthcare, drug pricing reforms) could impact demand for their services.

Operational Risks:

• Scalability Challenges: Rapid growth can strain operations. Ensuring scalability without compromising quality is essential.
• Supply Chain Disruptions: Dependence on suppliers for medications and products exposes them to supply chain risks.

Financial Risks:

• Capital Requirements: Expanding services and entering new markets require capital. Raising funds or managing debt could be challenging.
• Pricing Pressures: As telemedicine becomes more widespread, insurers and payers may negotiate lower reimbursement rates.

External Factors:

• Pandemic Uncertainty: The COVID-19 pandemic accelerated telemedicine adoption. However, post-pandemic behavior remains uncertain.
• Economic Conditions: Economic downturns can impact consumer spending on non-essential healthcare services.

In summary, while Hims & Hers Health has strong growth prospects, these risks should be closely monitored. Adaptability, regulatory compliance, and differentiation will be critical to their long-term success.

Valuation

3-Year Projection:

• Revenue: Assuming a 20% annual growth rate, the company’s revenue might reach around $1.5 billion.
• Profit Margins: If operational efficiency improves, profit margins could expand slightly.
• Valuation Multiple: The valuation multiple (such as price-to-sales ratio) might be influenced by market sentiment and industry trends. Conservatively, let’s assume a 15x price-to-sales ratio.

5-Year Projection:

• Revenue: With sustained growth and potential expansion into new markets or services, revenue could approach $2.4 billion (as estimated earlier).
• Profit Margins: Operational improvements and economies of scale may lead to better profit margins.
• Valuation Multiple: Assuming continued investor confidence, a 20x price-to-sales ratio could be reasonable.

10-Year Projection:

• Revenue: Over a decade, Hims & Hers Health might diversify further, reaching $5 billion in revenue.
• Profit Margins: As the company matures, profit margins could stabilize or improve.
• Valuation Multiple: A 25x price-to-sales ratio could reflect long-term growth prospects.